Abstract
Background: Palifermin is a recombinant keratinocyte growth factor (KGF) approved to decrease the incidence and severity of mucositis in stem cell transplantation. Furthermore, effects on the KGF receptor may modulate and minimize acute GVHD. Studies utilizing palifermin have been conducted in autologous SCT; however, literature regarding use in allogeneic SCT is minimal.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
